← Leaderboards
David M Rodman
University Of Colorado Denver
$4,846,234
Attributed
$4,846,234
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $411.4K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$4,846,234 · 6
By mechanism
R01$2,916,353 · 3
P01$1,535,256 · 1
M01$394,625 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Kurt R Stenmark$22,132,904
- Brian Barkley Graham$7,997,357
- Mark Robert Nicolls$22,256,364
- Rubin M Tuder$19,596,454
- Robin Shandas$12,521,834
Others in their field
Top investigators on “Pulmonary Hypertension”
- Marlene Rabinovitch · Stanford University$37,720,523
- Steven M Kawut · Columbia University Health Sciences$25,789,592
- Jason X.-J. Yuan · University Of California, San Diego$23,628,934
- Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru$23,127,355
- Mark Thomas Gladwin · Clinical Center$18,849,194
- Steven Herbert Abman · Johns Hopkins University$18,508,025
Research focus
Pulmonary HypertensionVascular Smooth MuscleVoltage Gated ChannelRespiratory HypoxiaPulmonary ArteryPotassium ChannelLaboratory RatEndothelinOxygen TensionVasomotionMembrane PotentialsCalcium FluxCalcium ChannelVoltage /Patch ClampVasoconstrictionHuman SubjectNitric OxideDrug Screening /EvaluationCystic FibrosisClinical ResearchHypoxiaInhalation Drug AdministrationBiotherapeutic AgentGenetically Modified Animals
Grant awards (23)
VRAC and Rho in pulmonary EC proliferation$411,367
P01 · FY2007 · HL · contact PI
VRAC and Rho in pulmonary EC proliferation$241,757
P01 · FY2006 · HL · contact PI
VRAC and Rho in pulmonary EC proliferation$236,592
P01 · FY2005 · HL
STUDY TO INVESTIGATE THE EFFICACY &SAFETY OF BIIL 284 BS IN ADULT &PED CF PTS$1,430
M01 · FY2005 · RR
Effects of BMPRII Mutations in Pulmonary Hypertension$496,411
R01 · FY2004 · HL
Study to Investigate the Efficacy &Safety of BIIL 284BS$11,701
M01 · FY2004 · RR
Effects of BMPRII Mutations in Pulmonary Hypertension$482,369
R01 · FY2003 · HL
VRAC and Rho in pulmonary EC proliferation$224,762
P01 · FY2003 · HL
HYPOXIA AND ET-1 EFFECT ON PA SMC EFFECT ON CHANNELS$372,157
R01 · FY2002 · HL
NOS GENE TRANSFER IN PULMONARY HYPERTENSION$309,242
R01 · FY2002 · HL
INHALED DOSES OF IB-367 IN ADULTS WITH CYSTIC FIBROSIS$190,747
M01 · FY2002 · RR
EFFECTS OF HYPOXIA, ET-1 AND NO ON PA SMC ION CHANNELS$123,636
P01 · FY2002 · HL
NOS GENE TRANSFER IN PULMONARY HYPERTENSION$302,852
R01 · FY2001 · HL
HYPOXIA AND ET-1 EFFECT ON PA SMC EFFECT ON CHANNELS$296,577
R01 · FY2001 · HL
INHALED DOSES OF IB-367 IN ADULTS WITH CYSTIC FIBROSIS$190,747
M01 · FY2001 · RR
EFFECTS OF HYPOXIA, ET-1 AND NO ON PA SMC ION CHANNELS$123,636
P01 · FY2001 · HL
HYPOXIA AND ET-1 EFFECT ON PA SMC EFFECT ON CHANNELS$69,460
R01 · FY2001 · HL
INHALED DOSES OF IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2001 · RR
NOS GENE TRANSFER IN PULMONARY HYPERTENSION$296,650
R01 · FY2000 · HL
HYPOXIA AND ET-1 EFFECT ON PA SMC EFFECT ON CHANNELS$290,635
R01 · FY2000 · HL
EFFECTS OF HYPOXIA, ET-1 AND NO ON PA SMC ION CHANNELS$173,506
P01 · FY2000 · HL
INHALED DOSES OF IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2000 · RR
INHALED DOSES OF IB-367 IN ADULTS WITH CYSTIC FIBROSIS$0
M01 · FY2000 · RR